Early stage support technologies

Infarnosys project: open for out-licensing and/or co-development partnership

SME Instrument Phase I winner project


Summary of invention:

Novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment.

Scientific background:

For both men and women, coronary artery disease is the leading cause of death in Europe in spite of the fact that 80% of premature heart diseases are preventable. Earlier and better diagnosis of cardiac ischemia and reperfusion injury is crucial for reducing the number of deaths connected to cardiovascular diseases.  Measuring MMP and nitrotyrosine levels enables predicting the occurrence of heart attack and helps to start the treatment much earlier. Our diagnostic marker combination has already been tested in several pre-clinical studies and in a pilot clinical study (Bencsik et al, Eur J Clin Invest, 2015).


– novel biomarker diagnostic system for earlier and better diagnosis of cardiac ischemia/reperfusion injury
– prediction of the effectiveness of cardioprotective treatments
– automated zymography-based device for the detection of MMP-2 and MMP-9 activities as a Minimum Viable Product for research market entry


– market viability confirmed
– project is based on H2020 SME Instrument “Champion” project
– immediate and growing need in research market segment for automated gelatin zymography device
– Minimum Viable Product for research market entry replaces current laborious, skilful, and time-consuming lab work
– earlier and better diagnosis of cardiac ischemia/reperfusion injury as compared to currently available methods
– prediction of the effectiveness of cardioprotective treatments

Planned project duration:

24 months up to Minimum Viable Product

The project is open for co-development and/or investors. For further details contact us: businessdevelopment@pharmahungary.com.

VEZICS: Highly efficient, scalable chromatography platform for high-quality exosome isolation

SME Instrument Phase I winner project

 Vezics logo_png_7Dec2017


Despite the enormous interest in the role of exosomes in cancer and other diseases, and their use as biomarkers for diagnosis and as therapeutical tools, there is no consensus on reliable protocols for their isolation. This constitutes probably the greatest barrier in realising exosomes’ full potential. Recently, more and more laboratories are starting to work with size exclusion chromatography (SEC) for exosome isolation. However, despite all its advantages, currently available SEC technology is not optimised for this purpose. We are developing a novel platform for exosome isolation based on SEC. Capitalising on very promising research results, the Vezics platform intends to offer all the advantages of SEC, while eliminating its disadvantages with regards to exosome isolation. As high quality isolation of exosomes is a prerequisite for all exosome applications, we expect our development to have a considerable positive impact across the entire spectrum; be it research, diagnostic or therapeutic use of exosomes. This is a high risk / high reward project targeting a yet undeveloped market with extremely high growth potential.

Scientific background:

We have shown that exosomes can be obtained by SEC with qualities and quantities sufficient for analytical investigation: https://www.ncbi.nlm.nih.gov/pubmed/26690353.

Planned project duration:

•    4 months up to Feasibility Study
•    18 months up to Minimum Viable Product



The online version of miRNAtarget has been launched!

MirRNAtarget is a software tool under continuous development for the analysis of the targets of differentially expressed microRNAs (miRNAs).

•    to analyze the targets of miRNAs from a network theoretical perspective
•    to predict the most probable targets of differentially expressed miRNAs

•    MiRNAtarget relies on multiple miRNA-target interaction databases
•    simple and powerful network theoretical approach to identify the most probable targets of differentially expressed miRNAs
•    increased coverage of possible miRNA-target interactions compared to experimentally validated databases
•    higher accuracy than available predicted miRNA-target interaction databases
•    interactions predicted by miRNAtarget has been successfully validated in two animal studies (submitted for publication)

Recommended for:
•    basic researchers
•    small biotech companies
•    pharmaceutical industry

For more information see: www.miRNAtarget.com.

This study was supported by the National Research, Development and Innovation Office of Hungary (NKFIA; NVKP-16-1-2016-0017 National Heart Program).